• Jeffrey A Bluestone, Alan M Krensky, Laurence A Turka, Daniel Rotrosen, and Jeffrey B Matthews.
• Immune Tolerance Network, University of California, San Francisco, San Francisco, CA 94107, USA.
• Sci Transl Med. 2010 Feb 17; 2 (19): 19cm7.

AbstractThe U.S. National Institutes of Health Roadmap and the U.S. Food and Drug Administration's Critical Path Initiative have endorsed the establishment of large academic clinical research networks as part of the solution to the growing divide between increased R&D spending and the lagging number of new drugs making it to market. Clearly, the role of these networks as translational science incubators that complement industry-sponsored programs is laudable and much-needed. However, the path to success for such organizations is less clear. Here, drawing on the experiences of the Immune Tolerance Network, a multidisciplinary clinical research network founded in 1999, we discuss some of the barriers inherent in developing such consortia and offer firsthand insight into the planning, resources, and organizational infrastructure required for a successful research program.

21 keywords...

hide…